2H0 Stock Chart & Stats
€0.77
-€0.03(-2.34%)
At close: 4:00 PM EDT
€0.77
-€0.03(-2.34%)
Day’s Range― - ―
52-Week Range€0.73 - €8.25
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€7.34M
Enterprise Value€11.54
Total Cash (Recent Filing)€1.72M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-1.24
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding6,545,995
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)8.69
Price to Sales (P/S)0.00
P/FCF Ratio-3.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt EliminationDebt elimination reduces interest and refinancing pressure compared with prior years, giving the company a cleaner capital structure. However, this benefit does not resolve the broader funding challenge because operations continue to consume cash.
Governance RefreshAdding independent directors and creating a Compensation Committee broadens oversight and may strengthen governance during the portfolio transition. Its durable benefit depends on whether the refreshed board improves execution and capital allocation.
Reoriented Development PortfolioA reoriented hematologic-disease portfolio and lead stem-cell-mobilization program provide a defined potential development path beyond halted legacy work. If advanced, this could restore strategic focus, though clinical validation remains necessary.
Bears Say
No Commercial RevenueZero TTM revenue, negative gross profit, and ongoing EBIT and net losses show the company lacks a commercial earnings base. Without product sales or another durable revenue stream, self-funded growth and operating sustainability remain limited.
Persistent Cash BurnOperating cash flow of -$6.7M and FCF of -$6.4M demonstrate continued funding needs. Equity fell to about $1.0M from $3.9M in 2025, so ongoing losses may require additional financing and dilute existing holders.
Pipeline DiscontinuityThe restructuring halted prior clinical and development work, while management is pursuing strategic alternatives. This weakens pipeline continuity and leaves the value-creation route dependent on a new program and disciplined execution.
Exicure News
2H0 FAQ
What was Exicure Inc’s price range in the past 12 months?
Exicure Inc lowest stock price was €0.73 and its highest was €8.25 in the past 12 months.
What is Exicure Inc’s market cap?
Exicure Inc’s market cap is €7.34M.
When is Exicure Inc’s upcoming earnings report date?
Exicure Inc’s upcoming earnings report date is Nov 12, 2026 which is in 70 days.
How were Exicure Inc’s earnings last quarter?
Exicure Inc released its earnings results on Aug 07, 2026. The company reported -€0.152 earnings per share for the quarter.
Is Exicure Inc overvalued?
According to Wall Street analysts Exicure Inc’s price is currently Overvalued.
Does Exicure Inc pay dividends?
Exicure Inc does not currently pay dividends.
What is Exicure Inc’s EPS estimate?
Exicure Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Exicure Inc have?
Exicure Inc has 6,545,995 shares outstanding.
What happened to Exicure Inc’s price movement after its last earnings report?
Exicure Inc reported an EPS of -€0.152 in its last earnings report. Following the earnings report the stock price went down -13.679%.
Which hedge fund is a major shareholder of Exicure Inc?
Currently, no hedge funds are holding shares in DE:2H0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Exicure Inc
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.